CEO statement

Idiopathic pulmonary fibrosis is a condition that robs patients of their ability to breathe. The associated cough can have a profound impact on the patient’s quality of life, affecting work, sleep, and personal relationships.

We have a strong strategic commitment in dedicating ourselves to rare fibrotic lung diseases, and to bring truly life-changing medicines to patients. This means that we listen to the patient and find out how the disease impairs their life. It is so important for us to understand and respect those experiences and to build those insights into our development programmes. This will help expedite the progress of our medicines to regulators, payers, and ultimately patients.

We are proud of our complementary pipeline. VP01 has been shown preclinically to work through multi-modal pathways, which may benefit complex diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis related pulmonary fibrosis (SSc).

A phase II study in SSc patients with Raynauds phenomenon started in December 2019. It had a fast initial recruitment but was paused in March due to the situation with Covid-19. In April we received approval for a phase II study with VP01 in COVID 19 patients from the UK regulatory agency MHRA.

In May, we received approval from MHRA to start a phase II study in IPF. Depending on the COVID-19 situation, we anticipate that patient recruitment can start during the third quarter 2020.

VP02 is a new formulation of an existing pharmaceutically active medicine and is currently in the preclinical stage. We are on target to enter clinical development with VP02 in 2020.

Our company’s distinctive approach springs from our collaborative nature and deep roots in world-class science. As one of the potential leaders in the treatment of fibrotic lung diseases, we are committed to bringing these transformational medicines to patients.